Poster presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA; 6–10 December 2016; Verma S et al. Ribociclib + letrozole vs placebo + letrozole in postmenopausal women with HR+/HER2– advanced breast cancer and a high disease burden. This evidence concerns the gene ERBB2 and breast carcinoma.